Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues
出版年份 2023 全文链接
标题
Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues
作者
关键词
-
出版物
PHARMACOLOGY & THERAPEUTICS
Volume 246, Issue -, Pages 108419
出版商
Elsevier BV
发表日期
2023-04-19
DOI
10.1016/j.pharmthera.2023.108419
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Classification of GBA1 Variants in Parkinson's Disease: The GBA1 ‐PD Browser
- (2023) Sitki Cem Parlar et al. MOVEMENT DISORDERS
- Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model
- (2022) Shi Yu Yang et al. HUMAN MOLECULAR GENETICS
- Lysosomal ceramides regulate Cathepsin B-mediated processing of saposin C and glucocerebrosidase activity
- (2022) Myung Jong Kim et al. HUMAN MOLECULAR GENETICS
- No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson’s Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance
- (2022) Adenrele Gleason et al. MOVEMENT DISORDERS
- Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models
- (2022) Susy Prieto Huarcaya et al. Autophagy
- Misfolded GBA/β-glucocerebrosidase impairs ER-quality control by chaperone-mediated autophagy in Parkinson disease
- (2022) Sheng-Han Kuo et al. Autophagy
- Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations
- (2022) Sara Grisanti et al. MOVEMENT DISORDERS
- Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments
- (2022) Matthew E. Gegg et al. NEUROBIOLOGY OF DISEASE
- Genetic heterogeneity on sleep disorders in Parkinson’s disease: a systematic review and meta-analysis
- (2022) Jingxuan Huang et al. Translational Neurodegeneration
- Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease
- (2022) Laura J. Smith et al. Frontiers in Neurology
- Prosaposin Reduces α-Synuclein in Cells and Saposin C Dislodges it from Glucosylceramide-enriched Lipid Membranes
- (2022) Rika Kojima et al. JOURNAL OF MOLECULAR NEUROSCIENCE
- Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology
- (2022) Alba Navarro-Romero et al. npj Parkinsons Disease
- Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions
- (2022) Casey L. Mahoney-Crane et al. JOURNAL OF NEUROSCIENCE
- A randomized single and multiple ascending dose study in healthy volunteers of LTI‐291, a centrally penetrant glucocerebrosidase activator
- (2021) Jonas M. Heijer et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Profiling the Biochemical Signature of GBA‐Related Parkinson's Disease in Peripheral Blood Mononuclear Cells
- (2021) Micol Avenali et al. MOVEMENT DISORDERS
- The Mutation Matters: CSF Profiles of GCase , Sphingolipids, α‐Synuclein in PD GBA
- (2021) Stefanie Lerche et al. MOVEMENT DISORDERS
- Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders
- (2021) Marzena Kurzawa-Akanbi et al. ACTA NEUROPATHOLOGICA
- Lewy Body–like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and α‐Synuclein Mutations
- (2021) Junghyun Jo et al. ANNALS OF NEUROLOGY
- Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity
- (2021) Nurit Omer et al. MOVEMENT DISORDERS
- Serum lipid profile among sporadic and familial forms of Parkinson’s disease
- (2021) Daniel Macías-García et al. npj Parkinsons Disease
- Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease
- (2021) Matthew Surface et al. MOVEMENT DISORDERS
- Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model
- (2021) Catherine Viel et al. Scientific Reports
- Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial
- (2021) M. Judith Peterschmitt et al. Journal of Parkinsons Disease
- Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson’s disease models
- (2021) Lena F. Burbulla et al. JCI Insight
- Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation
- (2021) Céline Galvagnion et al. BRAIN
- Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice
- (2020) Collin Challis et al. NATURE NEUROSCIENCE
- Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations
- (2020) Stephen Mullin et al. JAMA Neurology
- Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons
- (2020) Matthew E Gegg et al. HUMAN MOLECULAR GENETICS
- Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson’s disease
- (2020) Thomas B Stoker et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Substrate reduction therapy using Genz‐667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher disease
- (2020) Shani Blumenreich et al. JOURNAL OF NEUROCHEMISTRY
- Evaluating the Role of SNCA , LRRK2 , and GBA in Chinese Patients With Early‐Onset Parkinson's Disease
- (2020) Yongping Chen et al. MOVEMENT DISORDERS
- High Glucosylceramides and Low Anandamide Contribute to Sensory Loss and Pain in Parkinson's Disease
- (2020) Katharina Klatt‐Schreiner et al. MOVEMENT DISORDERS
- GBA ‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort
- (2020) Simona Petrucci et al. MOVEMENT DISORDERS
- GBA variants in REM sleep behavior disorder: a multicenter study
- (2020) Lynne Krohn et al. NEUROLOGY
- β-Glucocerebrosidase activity in GBA-linked Parkinson disease
- (2020) Young Eun Huh et al. NEUROLOGY
- Pro-cathepsin D, Prosaposin, and Progranulin: Lysosomal Networks in Parkinsonism
- (2020) Nahid Tayebi et al. TRENDS IN MOLECULAR MEDICINE
- Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial
- (2019) C. R. A. Silveira et al. BMC Neurology
- Insights into GBA Parkinson's disease pathology and therapy with induced pluripotent stem cell model systems
- (2019) Pascale Baden et al. NEUROBIOLOGY OF DISEASE
- Glucocerebrosidase and its relevance to Parkinson disease
- (2019) Jenny Do et al. Molecular Neurodegeneration
- Brain-First versus Gut-First Parkinson’s Disease: A Hypothesis
- (2019) Per Borghammer et al. Journal of Parkinsons Disease
- Ambroxol Hydrochloride Improves Motor Functions and Extends Survival in a Mouse Model of Familial Amyotrophic Lateral Sclerosis
- (2019) Alexandra Bouscary et al. Frontiers in Pharmacology
- Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy
- (2019) Yoon-Myung Kim et al. JOURNAL OF MEDICAL GENETICS
- Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
- (2019) Mylene Huebecker et al. Molecular Neurodegeneration
- Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha‐Synuclein Profiles
- (2019) Stefanie Lerche et al. MOVEMENT DISORDERS
- Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation
- (2019) Shi-yu Yang et al. NEUROBIOLOGY OF DISEASE
- Cholesterol and multilamellar bodies: Lysosomal dysfunction in GBA-Parkinson disease
- (2018) Patricia García-Sanz et al. Autophagy
- Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function
- (2018) Myung Jong Kim et al. HUMAN MOLECULAR GENETICS
- Features ofGBA-associated Parkinson’s disease at presentation in the UKTracking Parkinson’sstudy
- (2018) Naveed Malek et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies
- (2018) Tim E. Moors et al. MOLECULAR NEUROBIOLOGY
- Fetal gene therapy for neurodegenerative disease of infants
- (2018) Giulia Massaro et al. NATURE MEDICINE
- Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene
- (2018) Avner Thaler et al. PARKINSONISM & RELATED DISORDERS
- The Parkinson Pandemic—A Call to Action
- (2018) E. Ray Dorsey et al. JAMA Neurology
- Integrated Genetic Analysis of Racial Differences of Common GBA Variants in Parkinson's Disease: A Meta-Analysis
- (2018) Yuan Zhang et al. Frontiers in Molecular Neuroscience
- Chaperone-mediated autophagy as a therapeutic target for Parkinson disease
- (2018) Philip Campbell et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study
- (2018) Violetta Rozani et al. MOVEMENT DISORDERS
- Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons
- (2018) J. Magalhaes et al. Scientific Reports
- Lifetime risk of common neurological diseases in the elderly population
- (2018) Silvan Licher et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2018) E. Ray Dorsey et al. LANCET NEUROLOGY
- Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes
- (2018) Avner Thaler et al. MOVEMENT DISORDERS
- Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine
- (2018) Fabio Blandini et al. MOVEMENT DISORDERS
- The Emerging Evidence of the Parkinson Pandemic
- (2018) E. Ray Dorsey et al. Journal of Parkinsons Disease
- The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase
- (2018) Cathrine K. Fog et al. EBioMedicine
- Insights into the structural biology of Gaucher disease
- (2017) Laura Smith et al. EXPERIMENTAL NEUROLOGY
- Alpha-synuclein induces the unfolded protein response in Parkinson’s disease SNCA triplication iPSC-derived neurons
- (2017) Sabrina M Heman-Ackah et al. HUMAN MOLECULAR GENETICS
- GBA Analysis in Next-Generation Era
- (2017) Stefania Zampieri et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease
- (2017) Yumiko V. Taguchi et al. JOURNAL OF NEUROSCIENCE
- AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy
- (2017) Giuseppe Morabito et al. MOLECULAR THERAPY
- Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients
- (2017) Lucilla Parnetti et al. MOVEMENT DISORDERS
- N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease
- (2017) Patricia García-Sanz et al. MOVEMENT DISORDERS
- Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease
- (2017) S. Pchelina et al. NEUROSCIENCE LETTERS
- Serum lipid alterations in GBA -associated Parkinson's disease
- (2017) Leonor Correia Guedes et al. PARKINSONISM & RELATED DISORDERS
- Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
- (2017) S. Pablo Sardi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate
- (2017) Anna Migdalska-Richards et al. SYNAPSE
- The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson’s Disease
- (2017) Céline Galvagnion Journal of Parkinsons Disease
- A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers
- (2017) Shi-Yu Yang et al. Stem Cell Reports
- Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice
- (2016) Anna Migdalska-Richards et al. ANNALS OF NEUROLOGY
- Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's
- (2016) Ganqiang Liu et al. ANNALS OF NEUROLOGY
- Survival and dementia inGBA-associated Parkinson's disease: The mutation matters
- (2016) Roberto Cilia et al. ANNALS OF NEUROLOGY
- Endoplasmic reticulum and lysosomal Ca2+ stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts
- (2016) Bethan S. Kilpatrick et al. CELL CALCIUM
- Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease
- (2016) Olive Jung et al. Expert Review of Proteomics
- Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease
- (2016) Joana Magalhaes et al. HUMAN MOLECULAR GENETICS
- A New Glucocerebrosidase Chaperone Reduces -Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism
- (2016) E. Aflaki et al. JOURNAL OF NEUROSCIENCE
- Activation of -Glucocerebrosidase Reduces Pathological -Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons
- (2016) J. R. Mazzulli et al. JOURNAL OF NEUROSCIENCE
- A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin
- (2016) Kerri J. Kinghorn et al. JOURNAL OF NEUROSCIENCE
- ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons
- (2016) Hugo J.R. Fernandes et al. Stem Cell Reports
- Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study
- (2016) Aya Narita et al. Annals of Clinical and Translational Neurology
- Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease
- (2016) Jinlong Jian et al. EBioMedicine
- Association Between Progranulin and Gaucher Disease
- (2016) Jinlong Jian et al. EBioMedicine
- Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models
- (2016) Alvaro Sanchez-Martinez et al. Scientific Reports
- Glucocerebrosidase activity in Parkinson’s disease with and withoutGBAmutations
- (2015) Roy N. Alcalay et al. BRAIN
- Glucocerebrosidase 1 deficientDanio reriomirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death
- (2015) Marcus Keatinge et al. HUMAN MOLECULAR GENETICS
- Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies
- (2015) Davide Chiasserini et al. Molecular Neurodegeneration
- No evidence for substrate accumulation in Parkinson brains withGBAmutations
- (2015) Matthew E. Gegg et al. MOVEMENT DISORDERS
- Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons
- (2015) Emily M. Rocha et al. NEUROBIOLOGY OF DISEASE
- Differential effects of severe vs mild GBA mutations on Parkinson disease
- (2015) Z. Gan-Or et al. NEUROLOGY
- Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
- (2014) Karen E. Murphy et al. BRAIN
- Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells
- (2014) Alisdair McNeill et al. BRAIN
- The serum lipid profile of Parkinson's disease patients: a study from China
- (2014) Xiaoyan Guo et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Mutations in the glucocerebrosidase gene are responsible for Chinese patients with Parkinson’s disease
- (2014) Zhe Yu et al. JOURNAL OF HUMAN GENETICS
- GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study
- (2014) Kathrin Brockmann et al. MOVEMENT DISORDERS
- A GCase Chaperone Improves Motor Function in a Mouse Model of Synucleinopathy
- (2014) Franziska Richter et al. Neurotherapeutics
- iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis
- (2014) David C. Schöndorf et al. Nature Communications
- iPSC-Derived Dopamine Neurons Reveal Differences between Monozygotic Twins Discordant for Parkinson’s Disease
- (2014) Chris M. Woodard et al. Cell Reports
- Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s Disease
- (2013) Laura D. Osellame et al. Cell Metabolism
- Functional analysis of 11 novel GBA alleles
- (2013) Erika Malini et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease
- (2013) Sarah K. Abbott et al. MOVEMENT DISORDERS
- Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study
- (2013) Michelle M. Mielke et al. PLoS One
- Reduced Serum Levels of Triglyceride, Very Low Density Lipoprotein Cholesterol and Apolipoprotein B in Parkinson’s Disease Patients
- (2013) Qiang Wei et al. PLoS One
- Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones
- (2013) C. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies
- (2013) S. Pablo Sardi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies
- (2013) Michael A. Nalls et al. JAMA Neurology
- Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
- (2012) Matthew E. Gegg et al. ANNALS OF NEUROLOGY
- Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling
- (2012) Huma Q. Rana et al. GENETICS IN MEDICINE
- Discovery, Structure–Activity Relationship, and Biological Evaluation of Noninhibitory Small Molecule Chaperones of Glucocerebrosidase
- (2012) Samarjit Patnaik et al. JOURNAL OF MEDICINAL CHEMISTRY
- Glucocerebrosidase Mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease
- (2012) Marzena Kurzawa-Akanbi et al. JOURNAL OF NEUROCHEMISTRY
- Endoplasmic Reticulum Stress Is Important for the Manifestations of -Synucleinopathy In Vivo
- (2012) E. Colla et al. JOURNAL OF NEUROSCIENCE
- The link between the GBA gene and parkinsonism
- (2012) Ellen Sidransky et al. LANCET NEUROLOGY
- The role of saposin C in Gaucher disease
- (2012) Rafael J. Tamargo et al. MOLECULAR GENETICS AND METABOLISM
- Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers
- (2012) M. Anheim et al. NEUROLOGY
- The French Gaucher’s disease registry: clinical characteristics, complications and treatment of 562 patients
- (2012) Jérôme Stirnemann et al. Orphanet Journal of Rare Diseases
- High Throughput Screening for Small Molecule Therapy for Gaucher Disease Using Patient Tissue as the Source of Mutant Glucocerebrosidase
- (2012) Ehud Goldin et al. PLoS One
- Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies
- (2011) Joseph R. Mazzulli et al. CELL
- Ex Vivoandin VivoEffects of Isofagomine on Acid β-Glucosidase Variants and Substrate Levels in Gaucher Disease
- (2011) Ying Sun et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Is E326K glucocerebrosidase a polymorphic or pathological variant?
- (2011) Benjamin Liou et al. MOLECULAR GENETICS AND METABOLISM
- GBA-associated PD presents with nonmotor characteristics
- (2011) K. Brockmann et al. NEUROLOGY
- Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease
- (2011) J. Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CNS expression of glucocerebrosidase corrects -synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy
- (2011) S. P. Sardi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical progression in Parkinson disease and the neurobiology of axons
- (2010) Hsiao-Chun Cheng et al. ANNALS OF NEUROLOGY
- Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains
- (2010) Lydia Alvarez-Erviti et al. ARCHIVES OF NEUROLOGY
- Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant
- (2010) Inna Bendikov-Bar et al. BLOOD CELLS MOLECULES AND DISEASES
- The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of β-glucosidase
- (2010) Richie Khanna et al. FEBS Journal
- Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson’s disease
- (2010) Arianna Bellucci et al. JOURNAL OF NEUROCHEMISTRY
- Pathogenic Lysosomal Depletion in Parkinson's Disease
- (2010) B. Dehay et al. JOURNAL OF NEUROSCIENCE
- Effects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and Stability
- (2009) Raquel L. Lieberman et al. BIOCHEMISTRY
- Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease
- (2009) Gustavo H. B. Maegawa et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Incidence and remaining lifetime risk of Parkinson disease in advanced age
- (2009) J. A. Driver et al. NEUROLOGY
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
- (2009) E. Sidransky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phenotype, diagnosis, and treatment of Gaucher's disease
- (2008) Gregory A Grabowski LANCET
- Total cholesterol and the risk of Parkinson disease
- (2008) G. Hu et al. NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started